News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Approves QIAGEN N.V. (QGEN) KRAS Test for Use With Eli Lilly and Company (LLY) and Bristol-Myers Squibb Company (BMY)'s Cancer Drug Erbitux


7/9/2012 6:26:46 AM

QIAGEN NV has received US FDA approval to market the therascreen KRAS RGQ PCR Kit (therascreen KRAS test) to provide guidance on the use of Erbitux (cetuximab) as a treatment in patients with metastatic colorectal cancer. The US FDA approval of the KRAS test kit marks a milestone in QIAGEN's global expansion of its Personalized Healthcare franchise which includes an industry-leading portfolio of molecular companion diagnostics to aid treatment decisions in oncology. QIAGEN already markets a broad range of companion diagnostic tests covering 30 biomarkers in Europe, Asia/Pacific and Japan.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES